Evidence map›Paper›PMID 31332068›Full record

ArticleAntimicrobial agents and chemotherapy2019

Single-Center Investigation of the Pharmacokinetics of WCK 4282 (Cefepime-Tazobactam Combination) in Renal Impairment.

Richard A Preston, Grigor Mamikonyan, Mushtaque Mastim, Dyal Garg, Christopher J Kemper, Allan Xu, Ravindra Yeole, Rajesh Chavan, H David Friedland, Ashima Bhatia

Open access · bronzeAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Richard A PrestonClinical Pharmacology Research Unit, Division of Clinical Pharmacology, Department of Medicine, Miller School of Medicine, University of Miami, Miami, Florida, USA rpreston@med.miami.edu.
Grigor MamikonyanClinartis LLC, Hollywood, Florida, USA.
Mushtaque MastimWockhardt Limited, Mumbai, India.
Dyal GargClinical Research Services, Boynton Beach, Florida, USA.
Christopher J KemperPharma Navigators, LLC, Lawrenceville, New Jersey, USA.
Allan XuKeystone Bioanalytical Inc., North Wales, Pennsylvania, USA.
Ravindra YeoleWockhardt Limited, Mumbai, India.
Rajesh ChavanWockhardt Limited, Mumbai, India.
H David FriedlandWockhardt's Morton Grove Pharmaceutical Inc., Morton Grove, Illinois, USA.
Ashima BhatiaWockhardt Limited, Mumbai, India.
Wockhardt Hospitals · INJackson Memorial Hospital · USWockhardt (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

WCK 4282 is a combination product of cefepime (FEP) and tazobactam (TAZ) in a 1:1 ratio currently under development for the treatment of multidrug-resistant Gram-negative bacterial infections. We investigated the effect of renal impairment on the pharmacokinetics (PK) and safety of WCK 4282 in 48 subjects with various degrees of renal function. Subjects were categorized on the basis of their Cockcroft-Gault equation-estimated creatinine clearance (CL

Indexed as

AgedAnti-Bacterial AgentsArea Under CurveCefepimeDrug CombinationsFemaleHumansMaleMiddle AgedRenal InsufficiencyTazobactamAnti-Bacterial AgentsCefepimeDrug CombinationsTazobactamantibacterial agentsbacterialGram-negative bacterial infectionsmultidrug resistanceβ-lactamases

Identifiers

PMID31332068
PMCPMC6761517
OpenAlexW2964349392

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.